US equities
|
INTC
$64.03
▼-30.46%
NVDA
$203.06
▼-4.96%
MU
$870.66
▼-6.81%
AMZN
$239.72
▼-1.67%
SNDK
$1,136.04
▼-14.59%
AMD
$498.53
▼-11.99%
AAPL
$344.23
▼-1.34%
GOOGL
$278.76
▼-1.78%
INTC
$64.03
▼-30.46%
NVDA
$203.06
▼-4.96%
MU
$870.66
▼-6.81%
AMZN
$239.72
▼-1.67%
SNDK
$1,136.04
▼-14.59%
AMD
$498.53
▼-11.99%
AAPL
$344.23
▼-1.34%
GOOGL
$278.76
▼-1.78%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Summit Therapeutics Inc. - Common Stock
(NQ:
SMMT
)
15.86
-0.34 (-2.13%)
Delayed Quote
Updated: 3:40 PM EDT, Oct 30, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Summit Therapeutics Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
19
20
Next >
Buy the Dip: 4 Stocks the Market Marked Down Too Far Ahead of Big Catalysts
↗
October 26, 2026
MercadoLibre, Novo Nordisk, Tyler Technologies and Summit Therapeutics trade below recent highs, yet each has earnings or catalysts that could shift sentiment.
Via
MarketBeat
Topics
Artificial Intelligence
Ivonescimab Plus Chemotherapy Demonstrates Overall Survival Superiority Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer in HARMONi-GI1 Study Conducted by Akeso in China
October 25, 2026
From
Summit Therapeutics
Via
Business Wire
Summit Therapeutics and Lunit Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology Development
October 23, 2026
From
Summit Therapeutics
Via
Business Wire
Summit Therapeutics (SMMT) Reports In-Line Q2 Loss; Stock Eases Amid Pivotal PDUFA Catalyst
↗
July 23, 2026
Via
Chartmill
Ivonescimab Data Sets across Multiple Tumor Types to Be Featured at ESMO 2026
October 22, 2026
From
Summit Therapeutics
Via
Business Wire
Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II / III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract Cancer
October 21, 2026
From
Summit Therapeutics
Via
Business Wire
Summit Therapeutics Announces Opening of Global Phase II Study of Ivonescimab-Based Regimens in Advanced Clear Cell Renal Cell Carcinoma
October 19, 2026
From
Summit Therapeutics
Via
Business Wire
AstraZeneca Completes $2 Billion Equity Investment in Summit Therapeutics
October 05, 2026
From
Summit Therapeutics
Via
Business Wire
Summit Therapeutics Announces Clinical Trial Collaboration with AstraZeneca and Daiichi Sankyo to Evaluate Ivonescimab in Combination with TROP2-Directed ADC Datroway
October 02, 2026
From
Summit Therapeutics
Via
Business Wire
These stocks that are showing activity before the opening bell on Tuesday.
↗
September 29, 2026
Via
Chartmill
AstraZeneca Makes $2 Billion Strategic Equity Investment in Summit Therapeutics
September 28, 2026
From
Summit Therapeutics
Via
Business Wire
HARMONi-GI1, a Phase III Trial Featuring Ivonescimab Plus Chemotherapy Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer from China, to Be Showcased in Presidential Symposium at ESMO 2026
September 22, 2026
From
Summit Therapeutics
Via
Business Wire
Updated HARMONi Data Presented at WCLC 2026 Demonstrate Consistent Overall Survival Results with Ivonescimab Plus Chemotherapy in Western and Asian Patients
September 15, 2026
From
Summit Therapeutics
Via
Business Wire
Ivonescimab Monotherapy Demonstrates a Statistically Significant & Clinically Meaningful Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in Akeso’s HARMONi-2 Study Conducted in China
September 13, 2026
From
Summit Therapeutics
Via
Business Wire
Ivonescimab Monotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in HARMONi-2 Study Conducted by Akeso in China
September 02, 2026
From
Summit Therapeutics
Via
Business Wire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
↗
August 26, 2026
Gainers Nuwellis (NASDAQ:NUWE) stock increased by 27.2% to $1.22 during Wednesday's pre-market session. The market value of their outstanding shares is at $3.0 million. Summit Therapeutics...
Via
Benzinga
Ivonescimab Plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Durvalumab Plus Chemotherapy in First-Line Advanced Biliary Tract Cancer in Single-Region Trial Conducted by Akeso in China
August 25, 2026
From
Summit Therapeutics
Via
Business Wire
Ivonescimab Plus Chemotherapy Global Phase III HARMONi Primary Analysis Results Published in The Lancet Oncology
August 25, 2026
From
Summit Therapeutics
Via
Business Wire
GLP-1 Drugs Are Huge. These 2 Stocks Are Tapping Into an Even Bigger Opportunity
↗
August 24, 2026
Could these 2 stocks outperform most GLP-1-focused companies over the medium term?
Via
The Motley Fool
Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for First-Line Treatment of Patients with Squamous Non-Small Cell Lung Cancer
August 12, 2026
From
Summit Therapeutics
Via
Business Wire
Lowey Dannenberg, P.C. is Investigating Summit Therapeutics Inc. (NASDAQ: SMMT) for Potential Breaches of Fiduciary Duty
August 06, 2026
From
Lowey Dannenberg, P.C.
Via
GlobeNewswire
Summit Therapeutics Further Expands Ivonescimab Global Development Program with Phase II/III HARMONi-GU1 Study in 1L Bladder Cancer
August 05, 2026
From
Summit Therapeutics
Via
Business Wire
Summit Therapeutics Q2 Earnings Call Highlights
↗
July 23, 2026
Summit Therapeutics (NASDAQ:SMMT) executives used the company’s latest earnings call to emphasize updated survival data for ivonescimab, outline the timing of key late-stage trial readouts and detail...
Via
MarketBeat
Topics
Earnings
Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter and Six Months Ended June 30, 2026
July 23, 2026
From
Summit Therapeutics
Via
Business Wire
Arcus Biosciences and Summit Therapeutics Enter into Clinical Trial Collaboration to Evaluate Casdatifan Combined with Ivonescimab in Kidney Cancer
July 22, 2026
From
Summit Therapeutics
Via
Business Wire
Ivonescimab Plus Chemotherapy Shows Consistent, Favorable Overall Survival Results in Western and Asian Patients in Updated Analysis from Global Phase III HARMONi Study
July 22, 2026
From
Summit Therapeutics
Via
Business Wire
Summit Therapeutics to Host Second Quarter 2026 Financial Results & Operational Progress Call on July 23, 2026
July 16, 2026
From
Summit Therapeutics
Via
Business Wire
Summit Therapeutics Signs Agreement to Sell Phase III Asset Ridinilazole to Biossil, Inc.
July 14, 2026
From
Summit Therapeutics
Via
Business Wire
Recursion Pharmaceuticals vs. Summit Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
↗
June 30, 2026
Recursion harnesses AI for large-scale drug discovery, while Summit's betting on a single oncology candidate. How do their financials and risk profiles stack up?
Via
The Motley Fool
Topics
Artificial Intelligence
Summit Therapeutics Announces Proposed Public Offering of Common Stock
June 09, 2026
From
Summit Therapeutics
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
...
19
20
Next >
